Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Will Weigh Three New Tech Assessments On Genetic Testing For Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Two of the assessments are intended to inform an upcoming Medicare Evidence Development and Coverage Advisory Committee meeting.

You may also be interested in...



Molecular Dx Labs Fret Over Medicare Payment Setting, Or, In Some Cases, Lack Thereof

The industry’s angst is growing several months after CMS announced a plan to task contractors with independently setting regional payments for more than 100 new molecular diagnostic codes. A breakdown in the process so far, stakeholders say, could have a lasting impact on small, venture-backed labs.

Genetic Testing, But No Drugs, On Revised List Of Potential Medicare NCD Topics

CMS includes genetic testing on its updated list of potential topics for Medicare national coverage determinations, released Nov. 27. But no biopharmaceuticals are on the list this time around.

AHRQ Finds Breast Cancer Tops List Of New Genetic Oncology Tests

The Agency for Healthcare Research and Quality has identified 38 new genetic tests for cancer that have entered U.S. or overseas markets since 2006, with breast cancer the most common disease target.

Related Content

Topics

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel